Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with andes virus

Journal of Virology

Volumn 85, Issue 23, 2011, Pages 12781-12791

  Brown, Kyle S ^a,b   Safronetz, David ^c   Marzi, Andrea ^c   Ebihara, Hideki ^c   Feldmann, Heinz ^a,b,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDES VIRUS SURFACE GLYCOPROTEIN PRECURSOR; CELL SURFACE PROTEIN; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS VACCINE; VIRUS VECTOR; ZAIRE EBOLA VIRUS GLYCOPROTEIN;

ANDES VIRUS; ANDES VIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; HANTAVIRUS; HANTAVIRUS INFECTION; HANTAVIRUS PULMONARY SYNDROME; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; INNATE IMMUNITY; LIVER LEVEL; LUNG PARENCHYMA; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROVOCATION TEST; SEROCONVERSION; SYRIAN HAMSTER; TISSUE LEVEL; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; GENETIC VECTORS; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; KIDNEY; MESOCRICETUS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, VIRAL; VACCINATION; VERO CELLS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL VACCINES;

ANDES VIRUS; ANIMALIA; CRICETINAE; HANTAVIRUS; MESOCRICETUS AURATUS; VESICULAR STOMATITIS VIRUS;

EID: 81255173592     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00794-11     Document Type: Article

References (74)

1. Arikawa, J., A. L. Schmaljohn, J. M. Dalrymple, and C. S. Schmaljohn. 1989. Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J. Gen. Virol. 70(Pt 3):615-624.
2. Bharadwaj, M., et al. 2002. Genetic vaccines protect against Sin Nombre hantavirus challenge in the deer mouse (Peromyscus maniculatus). J. Gen. Virol. 83:1745-1751.
3. Bharadwaj, M., R. Nofchissey, D. Goade, F. Koster, and B. Hjelle. 2000. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J. Infect. Dis. 182:43-48.
4. Brody, J. A., G. F. Fischer, and P. H. Peralta. 1967. Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am. J. Epidemiol. 86:158-161.
5. Campen, M. J., M. L. Milazzo, C. F. Fulhorst, C. J. Obot Akata, and F. Koster. 2006. Characterization of shock in a hamster model of hantavirus infection. Virology 356:45-49.
6. Carroll, D. S., et al. 2005. Hantavirus pulmonary syndrome in Central Bolivia: relationships between reservoir hosts, habitats, and viral genotypes. Am. J. Trop. Med. Hyg. 72:42-46.
7. Chu, Y. K., G. B. Jennings, and C. S. Schmaljohn. 1995. A vaccinia virusvectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J. Virol. 69:6417-6423.
8. Chu, Y. K., et al. 1994. Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae. Virology 198:196-204.
9. Cobleigh, M. A., L. Buonocore, S. L. Uprichard, J. K. Rose, and M. D. Robek. 2010. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. J. Virol. 84: 7513-7522.
10. Custer, D. M., E. Thompson, C. S. Schmaljohn, T. G. Ksiazek, and J. W. Hooper. 2003. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virusMgenome segment-based DNA vaccine. J. Virol. 77:9894-9905.
11. Enria, D. A., A. M. Briggiler, N. Pini, and S. Levis. 2001. Clinical manifestations of New World hantaviruses. Curr. Top. Microbiol. Immunol. 256: 117-134.
12. Feldmann, H., et al. 2007. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3:e2.
13. Fultz, P. N., J. A. Shadduck, C. Y. Kang, and J. W. Streilein. 1981. Genetic analysis of resistance to lethal infections of vesicular stomatitis virus in Syrian hamsters. Infect. Immun. 32:1007-1013.
14. Fultz, P. N., J. A. Shadduck, C. Y. Kang, and J. W. Streilein. 1981. Involvement of cells of hematopoietic origin in genetically determined resistance of Syrian hamsters to vesicular stomatitis virus. Infect. Immun. 34:540-549.
15. Garbutt, M., et al. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78:5458-5465.
16. Geisbert, T. W., et al. 2008. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4:e1000225.
17. Geisbert, T. W., et al. 2008. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 82:5664-5668.
18. Geisbert, T. W., et al. 2009. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83:7296-7304.
19. Geisbert, T. W., et al. 2010. Postexposure treatment of Marburg virus infection. Emerg. Infect. Dis. 16:1119-1122.
20. Haglund, K., J. Forman, H. G. Krausslich, and J. K. Rose. 2000. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268:112-121.
21. Hao, H., et al. 2008. Genetic immunization with hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2. Genet. Vaccines Ther. 6:15.
22. Hensley, L. E., et al. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 6:e1000904.
23. Hooper, J. W., D. M. Custer, J. Smith, and V. Wahl-Jensen. 2006. Hantaan/ Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347:208-216.
24. Hooper, J. W., A. M. Ferro, and V. Wahl-Jensen. 2008. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J. Virol. 82:1332-1338.
25. Hooper, J. W., K. I. Kamrud, F. Elgh, D. Custer, and C. S. Schmaljohn. 1999. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255:269-278.
26. Hooper, J. W., T. Larsen, D. M. Custer, and C. S. Schmaljohn. 2001. A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6-14.
27. Iyer, A. V., et al. 2009. Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27:893-903.
28. Jones, S. M., et al. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
29. Jonsson, C. B., J. Hooper, and G. Mertz. 2008. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 78:162-169.
30. Khaiboullina, S. F., S. P. Morzunov, and S. C. St. Jeor. 2005. Hantaviruses: molecular biology, evolution and pathogenesis. Curr. Mol. Med. 5:773-790.
31. Khan, A. S., T. G. Ksiazek, and C. J. Peters. 1996. Hantavirus pulmonary syndrome. Lancet 347:739-741.
32. Kretzschmar, E., L. Buonocore, M. J. Schnell, and J. K. Rose. 1997. Highefficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J. Virol. 71:5982-5989.
33. Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:4477-4481.
34. Lazaro, M. E., et al. 2007. Clusters of hantavirus infection, southern Argentina. Emerg. Infect. Dis. 13:104-110.
35. Lee, B. H., et al. 2006. A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine 24:2928-2934.
36. Levis, S., J. E. Rowe, S. Morzunov, D. A. Enria, and S. St. Jeor. 1997. New hantaviruses causing hantavirus pulmonary syndrome in central Argentina. Lancet 349:998-999.
37. -ΔΔCTmethod. Methods 25: 402-408.
38. Lopez, N., P. Padula, C. Rossi, M. E. Lazaro, and M. T. Franze-Fernandez. 1996. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 220:223-226.
39. Lundkvist, A., and B. Niklasson. 1992. Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: identification of epitopes involved in neutralization. Arch. Virol. 126:93-105.
40. Lyles, D. S., and C. E. Rupprecht. 2007. Rhabdoviridae, p. 1364-1409. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
41. Maes, P., J. Clement, and M. Van Ranst. 2009. Recent approaches in hantavirus vaccine development. Expert Rev. Vaccines 8:67-76.
42. Martinez, I., L. L. Rodriguez, C. Jimenez, S. J. Pauszek, and G. W. Wertz. 2003. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J. Virol. 77:8039-8047.
43. Martinez, V. P., et al. 2005. Person-to-person transmission of Andes virus. Emerg. Infect. Dis. 11:1848-1853.
44. Meissner, J. D., J. E. Rowe, M. K. Borucki, and S. C. St. Jeor. 2002. Complete nucleotide sequence of a Chilean hantavirus. Virus Res. 89:131-143.
45. Mertz, G. J., et al. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39:1307-1313.
46. Nichol, S. T., et al. 2005. Bunyaviridae, p. 695-716. In C. M. Fauquet, M. A. Mayo, J. Manilfoff, U. Desselberger, and L. A. Ball (ed.), Virus taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, San Diego, CA.
47. Nichol, S. T., et al. 1993. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 262:914-917.
48. Noble, S., L. McLain, and N. J. Dimmock. 2004. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine 22:3018-3025.
49. Ogino, M., et al. 2003. Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul virus envelope proteins in a rapid and safe neutralization test. Clin. Diagn. Lab Immunol. 10:154-160.
50. Padula, P. J., et al. 1998. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 241:323-330.
51. Pensiero, M. N., G. B. Jennings, C. S. Schmaljohn, and J. Hay. 1988. Expression of the Hantaan virusMgenome segment by using a vaccinia virus recombinant. J. Virol. 62:696-702.
52. Peters, C. J., and A. S. Khan. 2002. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. Clin. Infect. Dis. 34:1224-1231.
53. Ravkov, E. V., S. T. Nichol, and R. W. Compans. 1997. Polarized entry and release in epithelial cells of Black Creek Canal virus, a New World hantavirus. J. Virol. 71:1147-1154.
54. Ray, N., J. Whidby, S. Stewart, J. W. Hooper, and A. Bertolotti-Ciarlet. 2010. Study of Andes virus entry and neutralization using a pseudovirion system. J. Virol. Methods 163:416-423.
55. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27:493-497.
56. Rizvanov, A. A., S. F. Khaiboullina, A. G. van Geelen, and S. C. St. Jeor. 2006. Replication and immunoactivity of the recombinant Peromyscus maniculatus cytomegalovirus expressing hantavirus G1 glycoprotein in vivo and in vitro. Vaccine 24:327-334.
57. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
58. Roberts, A., et al. 1998. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:4704-4711.
59. Rusnak, J. M., et al. 2009. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 81:68-76.
60. Safronetz, D., et al. 2009. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J. Virol. 83:7285-7295.
61. Sanchez, A., T. W. Geisbert, and H. Feldmann. 2007. Filoviridae, p. 1409-1448. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
62. Schmaljohn, C. 2009. Vaccines for hantaviruses. Vaccine 27(Suppl. 4):D61-D64.
63. Schmaljohn, C. S., and S. T. Nichol. 2007. Bunyaviridae, p. 1742-1789. In D. M. Knipe et al. (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
64. Schnell, M. J., et al. 1998. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J. 17:1289-1296.
65. Schnell, M. J., L. Buonocore, E. Kretzschmar, E. Johnson, and J. K. Rose. 1996. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. U. S. A. 93:11359-11365.
66. Schonrich, G., et al. 2008. Hantavirus-induced immunity in rodent reservoirs and humans. Immunol. Rev. 225:163-189.
67. Schwartz, J. A., et al. 2010. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J. Virol. 84:4611-4618.
68. Stoltz, M., C. Ahlm, A. Lundkvist, and J. Klingström. 2007. Lambda interferon (IFN-λ) in serum is decreased in hantavirus-infected patients, and in vitro-established infection is insensitive to treatment with all IFNs and inhibits IFN-γ-induced nitric oxide production. J. Virol. 81:8685-8691.
69. Sullivan, N. J., et al. 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3:e177.
70. Toro, J., et al. 1998. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg. Infect. Dis. 4:687-694.
71. Yang, Z. Q., et al. 1991. Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase. Chin. Med. J. (Engl.) 104:149-153.
72. Yuan, Z. G., et al. 2009. A single immunization with a recombinant canine adenovirus type 2 expressing the Seoul virus Gn glycoprotein confers protective immunity against Seoul virus in mice. Vaccine 27:5247-5251.
73. Yuan, Z. G., et al. 2010. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J. Gen. Virol. 91:1764-1771.
74. Zivcec, M., D. Safronetz, E. Haddock, H. Feldmann, and H. Ebihara. 2011. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Methods 368:24-35.